Overview

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Status:
Not yet recruiting

Trial end date:
2027-01-15

Target enrollment:

Participant gender:

Summary

This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and atezolizumab may kill more tumor cells in patients with metastatic castrate-resistant prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Utah

Collaborator:

National Cancer Institute (NCI)

Treatments:

Antibodies, Monoclonal
Atezolizumab